Enterprise Value
718.8M
Cash
398.6M
Avg Qtr Burn
-37.74M
Short % of Float
6.43%
Insider Ownership
29.99%
Institutional Own.
73.09%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Qinlock (ripretinib) (KIT & PDGFRA inhibitor) Details GIST (Gastrointestinal stromal tumors) (fourth-line) | Approved Quarterly sales | |
Vimseltinib (DCC-3014) (CSF1R inhibitor) Details Tenosynovial Giant Cell Tumors, Cancer | Phase 3 Data readout | |
Qinlock (Ripretinib) Details Gastrointestinal stromal tumors | Phase 3 Initiation | |
DCC-3116 (Inhibitor of ULK)+/- trametinib Details Solid tumor/s, Cancer | Phase 1/2 Update | |
DCC-3116 (Inhibitor of ULK)+encorafenib and cetuximab Details Solid tumor/s, Colorectal cancer , Cancer | Phase 1 Initiation | |
DCC-3116 (Inhibitor of ULK)+ripretinib Details Solid tumor/s, Gastrointestinal stromal tumors | Phase 1 Initiation | |
Rebastinib (TIE2 inhibitor) + Paclitaxel Details Solid tumor/s, Cancer | Failed Discontinued |